FY 2025 results: Galderma achieved record net sales of 5.207 billion USD, surpassing annual sales of 5 billion USD for the first time, growing 17.7% year-on-year at constant currency. Read more: https://t.co/UVsdfm05C1 #AdvancingDermatology #FYResults2025 $GALD

Late-breaking phase II data will be presented at #AAD2026 in children with moderate-to-severe atopic dermatitis. Learn more: https://t.co/9ET2JxmRdH #AdvancingDermatology #SkinScienceByGalderma

At the @AADskin meeting, 22 abstracts across Therapeutic Dermatology, Injectable Aesthetics and Dermatological Skincare, including late-breaking data in atopic dermatitis, will be presented. #AAD2026 https://t.co/59uLHJsbXW

Galderma receives U.S. FDA approval for Restylane® Contour™ for the correction of temple hollowing, expanding its use beyond cheek augmentation and midface contour deficiencies to support facial balance and harmony. Read more: https://t.co/V6TWRHra4R #SkinSciencebyGalderma

At #AMWC2026, Galderma will showcase data across Sculptra®, Restylane® and other injectable aesthetics products highlighting our holistic, future focused approach to aesthetics innovation. https://t.co/WNJ5wkrjdX #AdvancingDermatology #SkinSciencebyGalderma

Galderma buys back shares worth CHF 232 million in the context of accelerated bookbuild offering. $GALD Read more:

Galderma today announced the successful placement of a single-tranche EUR 500 million Eurobond. $GALD Read more:

Galderma unveils #Cetaphil AM/PM Antioxidant Serums — a science-driven defense + recovery system designed for sensitive skin. Powered by Gallic-AOX Power™ Technology, delivering greater antioxidant efficacy than Vitamin C with visible results in 7 days. https://t.co/pMnMSe4ZXZ

Our FY 2025 trading update call for investors takes place today, Thursday 5 March at 2 PM CET. Join live or watch the recording to learn about our record-breaking performance: https://t.co/utlWOVQkOB. #AdvancingDermatology #FYResults2025 $GALD

Beauty x Medicine returns with special guest Nicolas Hieronimus, CEO of L’Oréal. His four decades in the beauty industry have shown Nicolas that beauty isn’t just about meeting needs, but about “making dreams come true. Watch the full episode: https://t.co/79OnmcgZq9

We are presenting new data on the long-term efficacy and safety of our treatment for prurigo nodularis for up to three years at 2026 Winter Clinical™ Miami. Learn more: https://t.co/rzOLyp4jAO #AdvancingDermatology #SkinSciencebyGalderma #ForInvestors

Galderma secures approval in the EU, U.S., and Canada for its next-generation Restylane® syringe. Developed with practitioners to enhance ergonomics and injection control, this state-of-the art syringe supports consistent results. Read more: https://t.co/jOlOq4ar2P

We are pleased to announce the appointment of Luigi La Corte as CFO. He joins us with 30 years of financial leadership in healthcare and consumer businesses, and succeeds Thomas Dittrich. Read more: https://t.co/YrSiAnZ3Dd #AdvancingDermatology

We’re uncovering stories from nine real and diverse patients. See how Sculptra® continues to prove its versatility as a regenerative treatment. Learn more: https://t.co/n3AMC7MPoi #AdvancingDermatology #Sculptra

Galderma expands the Restylane® portfolio in Japan with the launch of Restylane Defyne™ and Refyne™, the first OBT™-based HA injectables approved in the market, supporting continued momentum across the Japan & Asia Pacific region. https://t.co/4877MBJVFK

We’re excited to share that the U.S. #FDA has accepted the Biologics License Application resubmission for our anti-wrinkle treatment for frown lines and crow’s feet. Learn more: https://t.co/LejUqiB4xe #AdvancingDermatology

Galderma unveils results from a global survey on the impact of menopause on the skin as part of its commitment to raising awareness and advancing science-backed aesthetic solutions. Explore the insights: https://t.co/nhWphHxHRz #AdvancingDermatology

Just launched: ‘Wake Up To Restylane®’ – a global campaign designed to meet the demand for natural-looking always-on results – helping people wake up looking refreshed and rested. Read more: https://t.co/7V3HE6fHRL #AdvancingDermatology #ForInvestors

We’re looking forward to the @imcascongress, where we will showcase our leadership in injectable aesthetic innovation through 10 posters and multiple educational sessions. Read more: https://t.co/idQGVLZusE #AdvancingDermatology

We’re excited to be part of TOXINS 2026 in Madrid, where we will present five posters and host a Masterclass session on our premium, science-backed anti-wrinkle treatment designed with PEARL™ Technology. https://t.co/sVuczXlFEo #AdvancingDermatology #ForInvestors